The panel examine toxicity and morbidity considerations for the use of hedgehog pathway inhibitors in BCC. This is a video synopsis/summary of a Peer Exchange involving Jason Luke, MD, FACP; ...
SAN DIEGO — Patients with idiopathic pulmonary fibrosis (IPF) had significant improvements in lung function and reversal of lung fibrosis measures after 12 weeks of therapy with an investigational ...
John Hood, PhD, cofounder and CEO of Endeavor BioMedicines, explains the potential advantages of ENV-101 during a time with very few treatments for idiopathic pulmonary fibrosis (IPF). There's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results